Back HCV Treatment

HCV Treatment

New Hepatitis C Drugs Reduce Mortality Risk in First 18 Months After Treatment

For the first time, a large study has demonstrated that treatment with direct-acting antivirals (DAAs) significantly reduces mortality among people with hepatitis C virus (HCV) infection, according to a recent report in Clinical Infectious Diseases.

alt

Read more:

IAS 2017: Glecaprevir/ Pibrentasvir Effective for People with HIV/HCV Coinfection

AbbVie's new 8-week pangenotypic regimen combining glecaprevir and pibrentasvir cured almost all HIV-positive people with hepatitis C coinfection in the EXPEDITION-2 study, according to a presentation at the 9th International AIDS Society Conference on HIV Science (IAS 2017) last month in Paris.

alt

Read more:

IAS 2017: Hepatitis C treatment is Effective and Feasible in Africa

Treatment for hepatitis C in sub-Saharan Africa can produce cure rates as high as those seen in industrialized countries, with high adherence and minimal side effects, according to a presentation this week at the 9th International AIDS Society Conference on HIV Science (IAS 2017) in Paris.

alt

Read more:

FDA Approves AbbVie's 8-Week Mavyret Combo Pill for Hepatitis C

On August 3 the U.S.Food and Drug Administration(FDA) approved AbbVie's new pangenotypic combination pill for people with hepatitis C virus (HCV) genotypes 1 through 6, to be marketed under the brand name Mavyret. Last week the European Commission gave similar approval for the European Union, where the coformulation will be sold as Maviret.

alt

Read more:

FDA Approves Gilead's Vosevi Combo Pill for Hepatitis C Re-treatment

On July 18, the U.S. Food and Drug Administration(FDA) approved Gilead Sciences' Vosevi, a new once-daily combination pill containing sofosbuvir, velpatasvir, and voxilaprevir. Vosevi was approved as "salvage therapy" for people with all hepatitis C virus (HCV) genotypes who were not previously cured with prior direct-acting antiviral therapy.

alt

Read more: